Potential conflict of interests forces board member out of Novo

This week, Novo Nordisk has said goodbye to one of its board members, Mary Szela. The reason is a potential conflict of interests related to Szela’s position as CEO of a US-based biotech company, which has moved into an area that Novo Nordisk also focuses on.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles